首頁 > 市場調查報告書 > 製藥

骨疾病

市場調查報告書

商品編碼

1358143

全球及中國骨質疏鬆藥物市場（依藥物類型及地區分類）

Global and China Osteoporosis Drugs Market, By Drug Type, By Geography

出版日期: 2023年09月11日 | 出版商:

Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2023年全球及中國骨質疏鬆藥物市場規模將達146億美元，預測期內（2023-2030年）年複合成長率為3.9%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	146億美元
實績資料	2018-2021	預測期	2023-2030
預測期年複合成長率	3.90%	2030年市場規模預測	191億美元

2023年全球及中國骨質疏鬆藥物市場佔有率（按藥物類型）

骨質疏鬆症的特徵是骨密度和品質下降，通常導致手腕、臀部和脊椎骨折。骨質疏鬆症是由要素引起的，包括遺傳、鈣、鎂和維生素D攝取不足、厭食等飲食障礙失調、缺乏運動和過量飲酒。骨質疏鬆症是由於骨骼密度和骨量降低以及骨質和結構改變而發生的骨骼疾病。骨強度降低會增加骨折的風險。隨著骨質疏鬆症患病的不斷增加，核准和上市的新骨質疏鬆症藥物數量不斷增加，預計將在預測期內顯著推動骨質疏鬆症藥物市場的成長。

市場動態

研發活動的活性化有助於全球和中國骨質疏鬆症藥物市場的成長。例如，根據Contemporary OB/GYN（致力於將科學轉化為臨床實踐的月刊）2023年3月10日發表的一項研究顯示，骨質疏鬆症的激素療法（HT）停經後，可以增加腰椎骨骼密度（ BMD）並防止骨質流失。在這項大型橫斷面研究中，目前和過去使用的多種類型的荷爾蒙療法，包括閉經女性使用的聯合荷爾蒙避孕和停經後療法，與停經後女性的骨骼保護相關，並且這些效果被證明即使在治療停止後。該論文還得出結論，停止荷爾蒙治療或改變給藥會影響骨骼健康，包括骨折風險。

研究的主要特點

本報告對全球和中國骨質疏鬆藥物市場進行了詳細分析，並呈現了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率。
它還揭示了各個細分市場的潛在收入機會，並為該市場說明了一系列有吸引力的投資提案。
它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
它根據公司亮點、產品系列、主要亮點、財務實績和策略等參數，介紹了全球和中國骨質疏鬆症治療市場的主要企業。
該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、類型經營團隊、市場擴張和行銷策略做出資訊的決策。
全球和中國骨質疏鬆症藥物市場報告面向該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
相關人員可以透過用於分析全球和中國骨質疏鬆藥物市場的各種策略矩陣來促進決策。

Merck KGaA
Lilly
Procter & Gamble
Enzo Biochem Inc.
Sanofi
Novartis AG
Wyeth Nutrition（A subsidiary of Pfizer Inc.）
Hoffmann-La Roche Ltd
GSP plc
UCB SA
Amgen Inc.
BeiGene, Inc.
Bone Biologics Corp
TEIJIN LIMITED
Eden Biologics（Formerly known as JHL Biotech Inc.）
Keros Therapeutics
Taro Pharmaceutical Industries Ltd.

第10章章

調查方法
關於出版商

簡介目錄

Product Code: CMI4018

The Global and China Osteoporosis Drugs Market is estimated to be valued at US$ 14.6 Bn in 2023 and is expected to exhibit a CAGR of 3.9% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 14.6 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	3.90%	2030 Value Projection:	US$ 19.1 Bn

Global and China Osteoporosis Drugs Market Share (%), by Drug Type, 2023

Global and China Osteoporosis Drugs Market - IMG1

Osteoporosis is characterized by a decrease in the density and quality of bones, which frequently leads to broken wrist, hip, and spine bones. Various factors responsible for osteoporosis include, genetic factors; low intake of calcium, magnesium, and vitamin D; eating disorders such as anorexia, inactivity & immobility, and excessive alcohol intake. Osteoporosis is a bone disease that develops when bone mineral density and bone mass decreases, or when the quality or structure of bone changes. This can lead to a decrease in bone strength that can increase the risk of broken bones (fractures). Increasing approvals and launches of novel osteoporosis drugs along with increasing prevalence of osteoporasis is expected to significantly drive the osteoporosis treatment market growth over forecast period.

Market Dynamics

The increasing research & development activities are attributed to the growth of the global and China osteoporosis drugs market. For instance, according to a study shared by Contemporary OB/GYN- a monthly publication dedicated to translating science into clinical practice, on March 10, 2023, Hormone therapy (HT) for osteoporosis can increase lumbar spine bone mineral density (BMD) and prevent bone loss in post menopausal women. The large cross-sectional study showed that current and prior use of multiple types of hormone therapies, including combined hormone contraception used in premenopausal women and menopause hormone therapies, were linked with bone protection in postmenopausal women and that these effects persisted after discontinuation of treatment. The article also concluded that stopping HT and varying doses impact bone health, including fracture risk.

Key features of the study:

This report provides an in-depth analysis of the global and China osteoporosis drugs market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global and China osteoporosis drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Merck KGaA, Lilly, Procter & Gamble, Enzo Biochem Inc., Sanofi, Novartis AG, Wyeth Nutrition (A subsidiary of Pfizer Inc.), F. Hoffmann-La Roche Ltd, GSK plc, UCB S.A., Amgen Inc., BeiGene, Inc., Bone Biologics Corp, TEIJIN LIMITED, Eden Biologics (Formerly known as JHL Biotech Inc.), Keros Therapeutics, and Taro Pharmaceutical Industries Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global and China osteoporosis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global and China osteoporosis drugs market.

Detailed Segmentation:

Global and China Osteoporosis Drugs Market, By Drug Type:
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
Global and China Osteoporosis Drugs Market, By Route of Administration:
- Oral
- Injectable
- Others
Global and China Osteoporosis Drugs Market, By Distribution Channel:
- Hospitall Pharmacies
- Online Pharmacies
- Retail Pharmacies
Global and China Osteoporosis Drugs Market, By Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Company Profiles
- Merck KGaA
- Lilly
- Procter & Gamble
- Enzo Biochem Inc.
- Sanofi
- Novartis AG
- Wyeth Nutrition (A subsidiary of Pfizer Inc.)
- F. Hoffmann-La Roche Ltd
- GSP plc
- UCB S.A.
- Amgen Inc.
- BeiGene, Inc.
- Bone Biologics Corp
- TEIJIN LIMITED
- Eden Biologics (Formerly known as JHL Biotech Inc.)
- Keros Therapeutics
- Taro Pharmaceutical Industries Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global and China Osteoporosis Drugs Market- COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global and China Osteoporosis Drugs Market, By Drug Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Bisphosphonates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others
Calcitonin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Hormone Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Selective Estrogen Receptor Modulators (SERMs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Parathyroid Hormone-Related Protein (PTHrP) Analog
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Rank Ligand (RANKL) Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Global and China Osteoporosis Drugs Market, By Route of Administration, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

7. Global and China Osteoporosis Drugs Market, By Distribution Channel, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global and China Osteoporosis Drugs Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2018-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
China
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018- 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Bn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Merck KGaA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Lilly
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Procter & Gamble
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Enzo Biochem Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Wyeth Nutrition (A subsidiary of Pfizer Inc.)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Hoffmann-La Roche Ltd
GSP plc
UCB S.A.
Amgen Inc.
BeiGene, Inc.
Bone Biologics Corp
TEIJIN LIMITED
Eden Biologics (Formerly known as JHL Biotech Inc.)
Keros Therapeutics
Taro Pharmaceutical Industries Ltd.